alternatives to glp-1 agonists Promising New Science on Weight Loss Drug Upcoming wave of hormone-based therapies
Description
Gastrointestinal symptoms: nausea (20%), diarrhea (15%), vomiting (11%), constipation (6%), dyspepsia (6%), abdominal pain (5%), eructation (4%), gastroesophageal reflux disease (3%), abdominal distension (2%) and flatulence (2%)
2021;12 doi: 10.3389/fendo.2021.735019
The weight loss of the low dose (0.03 mg/kg) group, medium dose (0.1 mg/kg) group, and high dose (0.33 mg/kg) group were about 2g, 4g, and 1g (8 weeks)
Most side effects of GLP- 1 and GLP- 1/GIP receptor agonists are mild to moderate and resolve over time
What medical comorbidities are associated with NAFLD
